Roche has struck a collaboration with Chinese startup Defand Therapeutics to discover and develop molecular glue medicines for cancer and immune-driven diseases, signaling a shift from licensing deals to shared discovery work. The parties did not disclose financial terms, but a source familiar with the agreement said the total potential value could approach $1 billion across milestones.